ライフサイエンスコーパス: diabetes mellitus

1 ion in beta-cell mass are hallmark events of diabetes mellitus.

2 sisted after adjustment for hypertension and diabetes mellitus.

3 rosclerosis, rheumatoid arthritis and type 2 diabetes mellitus.

4 ls or on samples obtained from patients with diabetes mellitus.

5 ardial dysfunction in experimental and human diabetes mellitus.

6 atrial fibrillation, and with versus without diabetes mellitus.

7 gs have improved our understanding of type 2 diabetes mellitus.

8 horter axial length, and lower prevalence of diabetes mellitus.

9 cute hyperglycaemic emergency in people with diabetes mellitus.

10 ical bills among nonelderly individuals with diabetes mellitus.

11 chronic obstructive lung disease, and type 2 diabetes mellitus.

12 tions in islet morphogenesis often result in diabetes mellitus.

13 mbined adverse health effects of obesity and diabetes mellitus.

14 tial component in the pathogenesis of type 1 diabetes mellitus.

15 ing of the metabolic disturbances that cause diabetes mellitus.

16 health, particularly among individuals with diabetes mellitus.

17 years old with a self-reported diagnosis of diabetes mellitus.

18 relationship between H. pylori infection and diabetes mellitus.

19 patients had fever on admission, and 58% had diabetes mellitus.

20 une disorders and metabolic diseases such as diabetes mellitus.

21 analysis models that excluded patients with diabetes mellitus.

22 pha (H + T), that mimic the common stress in diabetes mellitus.

23 ed secretion was associated with gestational diabetes mellitus.

24 pancreas transplantation cures their type I diabetes mellitus.

25 eral end points in patients with and without diabetes mellitus.

26 ly changed the treatment landscape of type 2 diabetes mellitus.

27 lcohol consumption is associated with type 2 diabetes mellitus.

28 crine insufficiency such as malnutrition and diabetes mellitus.

29 a cholesterol, seen in traditional models of diabetes mellitus.

30 cardiovascular death in patients with type 2 diabetes mellitus.

31 rget for the treatment of obesity and type 2 diabetes mellitus.

32 e-related disorders such as osteoporosis and diabetes mellitus.

33 n's weighted comorbidity index, and baseline diabetes mellitus.

34 ease or peripheral artery disease often have diabetes mellitus.

35 rse events in high-risk patients with type 2 diabetes mellitus.

36 cardiovascular disease risk in subjects with diabetes mellitus.

37 tations and sulfonylurea therapy in neonatal diabetes mellitus.

38 risk of complications than those with type 1 diabetes mellitus.

39 ing interventions for human diseases such as diabetes mellitus.

40 Severely obese donors more likely had diabetes mellitus (10.4% versus 3.1%, P<0.01) and hypert

41 particularly favorable in the patients with diabetes mellitus (2.7% versus 1.0%; Gail-Simon qualitat

42 l heart disease; 1.74 (95% CI 1.33-2.29) for diabetes mellitus; 2.22 (95% CI 1.58-3.11) for alcohol a

43 isease (95% CI, 836 000-864 000) and 269 000 diabetes mellitus (265 000-274 000) cases, gain 2.44 mil

44 Hypertension (55%), diabetes mellitus (31%), and chronic pulmonary disease (

45 ypertension (83.7%), hyperlipidemia (72.1%), diabetes mellitus (31.6%), and chronic kidney disease (2

46 ious PCI (mean age 68.2+/-7.8, female 19.4%, diabetes mellitus 35.7%, previous myocardial infarction

47 s; 3) using drugs or with hepatitis; 4) with diabetes mellitus; 5) consuming >1 alcoholic drink per w

48 paired renal function, heart failure, and/or diabetes mellitus, a larger absolute risk reduction for

49 isolated from donors with obesity or type 2 diabetes mellitus, AGO1 and THBS1 are expressed at highe

50 ection of dysglycemia associated with type 1 diabetes mellitus (allogenic islet transplantation), or

51 There were 10 341 patients with diabetes mellitus and 17 054 without diabetes mellitus i

52 Indeed, the increasing global prevalence of diabetes mellitus and an aging population has given rise

53 rial, randomly assigned patients with type 2 diabetes mellitus and atherosclerotic cardiovascular (CV

54 in obesity-linked diseases, including type 2 diabetes mellitus and atherosclerotic cardiovascular dis

55 Models assessed the role of known mediators (diabetes mellitus and BP) by adjusting for measured valu

56 Given the intersection between diabetes mellitus and cardiovascular disease (CVD), phar

57 We estimated incremental changes in diabetes mellitus and cardiovascular disease, quality-ad

58 ates of perceived energy surplus (ie, type 2 diabetes mellitus and chronic heart failure), but SGLT2

59 n tissues with age and in conditions such as diabetes mellitus and chronic kidney disease (CKD), and

60 Twenty patients with type 2 diabetes mellitus and chronic, stable heart failure comp

61 Besides the epidemics of type 2 diabetes mellitus and coronary heart disease already fac

62 ersus placebo in 17 160 patients with type 2 diabetes mellitus and either multiple risk factors for a

63 Patients with diabetes mellitus and elevated ECV had the worst outcome

64 at increased risk of developing gestational diabetes mellitus and have impaired glucose tolerance wh

65 Type 2 diabetes mellitus and hypertension are the most common c

66 Type 2 diabetes mellitus and hypertension are two major risk fa

67 cy is rising as older maternal age, obesity, diabetes mellitus and hypertension become more common in

68 sified preventive treatment of patients with diabetes mellitus and hypertension to slow and stabilize

69 for initial ASCVD events in US veterans with diabetes mellitus and improve model performance in this

70 eruricemia is common in patients with type 2 diabetes mellitus and is known to cause gout.

71 trial flutter (AFL) are associated with both diabetes mellitus and its related comorbidities, includi

72 k factors, including blood pressure, lipids, diabetes mellitus and lifestyle-related risk factors, as

73 ment of risk factors including hypertension, diabetes mellitus and lipid disorders, antiplatelet ther

74 e genes, ANK1, EPHX2 and LOX2, implicated in diabetes mellitus and lipid dysregulation.

75 lassical clinical picture can be preceded by diabetes mellitus and microcytic anaemia, which are cons

76 ructural changes in participants with type 2 diabetes mellitus and neuropathy.

77 om patients with liver disease especially in diabetes mellitus and non-alcoholic fatty liver disease

78 e worst outcomes compared with patients with diabetes mellitus and normal ECV or nondiabetics.

79 an be obtained in both preclinical models of diabetes mellitus and patients with diabetes mellitus fa

80 therapy at best delays progression of type 1 diabetes mellitus and points to opportunities to use the

81 After excluding participants with diabetes mellitus and quality control, association of si

82 In patients with diabetes mellitus and stable chest pain, coronary comput

83 ular risk factors (body mass index, smoking, diabetes mellitus and total cholesterol).

84 atient (7%) had HIV coinfection, 5 (36%) had diabetes mellitus, and 5/14 (36%) had previous treatment

85 ian age of 51 years old; 67 were men, 31 had diabetes mellitus, and 59 had left ventricular hypertrop

86 Male sex, diabetes mellitus, and baseline eGFR >=90 ml/min per 1.7

87 ses, particularly insulin resistance, type 2 diabetes mellitus, and cardiovascular disease.

88 resses the interplay between obesity, type 2 diabetes mellitus, and cardiovascular diseases.

89 isease states including hypertension, type 2 diabetes mellitus, and chronic kidney disease.

90 atrial fibrillation, existing heart failure, diabetes mellitus, and creatinine levels, apnea-hypopnea

91 The association of NASH with obesity, type 2 diabetes mellitus, and dyslipidemia has led to an emergi

92 , hyperlipidemia, cigarette smoking, type II diabetes mellitus, and end-stage renal disease requiring

93 , hyperlipidemia, cigarette smoking, type II diabetes mellitus, and end-stage renal disease requiring

94 comprised more patients with active smoking, diabetes mellitus, and higher severity scores (Simplifie

95 common risk factors, including hypertension, diabetes mellitus, and obesity, and serious complication

96 al CVD risk factors, including hypertension, diabetes mellitus, and obesity.

97 -8000 birr [AOR = 4.54;(1.31-15.7)], type II diabetes mellitus [AOR = 3.9;(1.6-9.6)], duration of dia

98 Obesity and type 2 diabetes mellitus are global emergencies and long noncod

99 ocardium of mice with streptozotocin-induced diabetes mellitus as compared to controls.

100 specimens obtained from patients with type 2 diabetes mellitus as compared to nondiabetic subjects.

101 ge-artery atherosclerotic stroke, IGFBP3 and diabetes mellitus as well as cFn and body mass index.

102 such as gastroesophageal reflux disease and diabetes mellitus, as well as emergent complications inc

103 osteoporosis, metabolic syndrome and type 2 diabetes mellitus, as well as other endocrine conditions

104 Male sex (beta=1.676; P=0.009), diabetes mellitus (beta=1.725; P=0.012), and statin use

105 The effect of H. pylori infection on diabetes mellitus (both types), type 1 and type 2 diabet

106 cally larger in patients with versus without diabetes mellitus, both subgroups derived similar benefi

107 (hypertension/heart failure, hyperlipidemia, diabetes mellitus), but were attenuated towards unity wi

108 Exposure to chronic hyperglycemia because of diabetes mellitus can lead to development and progressio

109 ellular carcinoma, solid organ malignancies, diabetes mellitus, cardiovascular disease, and obstructi

110 ly exclusive groups according to presence of diabetes mellitus, cardiovascular disease, or heart fail

111 uding 1575 CVD deaths) and 21 522 new type 2 diabetes mellitus cases, gaining 8749 quality-adjusted l

112 EDICT) to estimate reductions in CVD events, diabetes mellitus cases, gains in quality-adjusted life

113 and are now the primary therapy for neonatal diabetes mellitus caused by mutations in the genes encod

114 ciated with diseases such as obesity, type 2 diabetes mellitus, certain infections and some cancers.

115 ups of proteins and accumulate during aging, diabetes mellitus, chronic kidney disease and other chro

116 excluding secondary kidney diseases, such as diabetes mellitus) clearly revealed that almost half of

117 therapies as first-line management of type 2 diabetes mellitus, considering heart failure or kidney o

118 ions Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) randomized clinical trial.

119 Risk of diabetes mellitus, depression, and cardiovascular diseas

120 he levels of autoantibodies against AGEs and diabetes mellitus (DM 44% vs 24.4%; p = 0.05).

121 Canine diabetes mellitus (DM) affects 0.6% of the canine popula

122 ammation in the dorsal skin of patients with diabetes mellitus (DM) and DFU specimens compared with c

123 esearch has examined the association between diabetes mellitus (DM) and knee pain in people with oste

124 The association between incidence of diabetes mellitus (DM) and living conditions has not bee

125 Patients with diabetes mellitus (DM) are characterized by enhanced thr

126 ctive study evaluated a screening method for diabetes mellitus (DM) in patients with Stage III or IV

127 Diabetes mellitus (DM) increases tuberculosis (TB) risk.

128 ellitus (non-DM) heart transplanted (HTX) in diabetes mellitus (DM) recipients, this study conducted

129 Diabetes mellitus (DM) significantly increases myocardia

130 ed to the vitrectomy group 1:2 based on sex, diabetes mellitus (DM) status, region of the United Stat

131 had never been diagnosed with hypertension, diabetes mellitus (DM), and cancer before.

132 , though the metabolic consequences, such as diabetes mellitus (DM), are unclear.

133 e impairment is a well-known complication of diabetes mellitus (DM).

134 Atrial fibrillation (AF) is prevalent in diabetes mellitus (DM); however, the basis for this is u

135 on of muscle abnormalities related to type 2 diabetes mellitus (DM2) and DPN.PurposeTo assess skeleta

136 ayed healing wound model in rats with type 2 diabetes mellitus (DM2).

137 In patients with type 2 diabetes mellitus, ertugliflozin reduced the risk for fi

138 odels of diabetes mellitus and patients with diabetes mellitus facilitating the bi-directional moveme

139 ith contributions to cardiovascular disease, diabetes mellitus, fatty liver disease, and cancer.

140 at index diagnosis of IC, and diagnosis with diabetes mellitus) followed up patients from index diagn

141 ts both with (n=6922) and without (n=11 356) diabetes mellitus for the primary efficacy end point (ha

142 e of these imaging tools in the patient with diabetes mellitus from a mechanistic, therapeutic effect

143 Women with a history of gestational diabetes mellitus (GDM) have a 7-fold higher risk of dev

144 Gestational diabetes mellitus (GDM) is a hyperglycaemic imbalance fi

145 Gestational diabetes mellitus (GDM) is increasing worldwide and wome

146 ns to a healthy pregnancy and in gestational diabetes mellitus (GDM) remain poorly understood.

147 Gestational diabetes mellitus (GDM) shares phenotypic characteristic

148 (PG) concentrations, even below gestational diabetes mellitus (GDM) thresholds, are associated with

149 r <=2.5 mum (PM2.5)) and risk of gestational diabetes mellitus (GDM), while the association between h

150 ponectinemia is a risk factor of gestational diabetes mellitus (GDM).

151 which are further exacerbated by gestational diabetes mellitus (GDM).

152 le-blind trial in which patients with type 2 diabetes mellitus (glycated hemoglobin level, >=7%), chr

153 Household contacts who themselves had diabetes mellitus had increased odds of infection (OR: 7

154 failure phenotype in the specific context of diabetes mellitus, has not yet been fully resolved.

155 Nonelderly patients with diabetes mellitus have a high prevalence of financial ha

156 Cases of type 2 diabetes mellitus have significantly increased in recent

157 ardiovascular disease (moderate strength) or diabetes mellitus (high strength) to a lower SBP target

158 uded CKD, men, non-White race, hypertension, diabetes mellitus, higher body mass index, higher d-dime

159 , left ventricular ejection fraction, type 2 diabetes mellitus, history of myocardial infarction, Can

160 evel, impaired fasting glucose level, type 2 diabetes mellitus, hypertension (HT), and metabolic synd

161 major atherosclerotic risk factors including diabetes mellitus, hypertension, low-density lipoprotein

162 es with cardiovascular disease risk, but how diabetes mellitus impacts that step is unclear.

163 associated with an increased risk of type 1 diabetes mellitus in childhood, but the reasons are uncl

164 revious large registries' reports except for diabetes mellitus in patients with CLI.

165 tients with diabetes mellitus versus without diabetes mellitus in preventing major vascular events.

166 workup of stable chest pain in patients with diabetes mellitus in the context of recent landmark tria

167 ry CD4+ T cells is associated with prevalent diabetes mellitus in the general population.

168 Among participants with type 2 diabetes mellitus in the Look AHEAD trial, the intensive

169 ts with diabetes mellitus and 17 054 without diabetes mellitus in the overall trial.

170 ncluding dementia, macular degeneration, and diabetes mellitus, in epidemiological studies.

171 Diabetes mellitus, inadequate implant restoration, singl

172 A total of 17 160 patients with type 2 diabetes mellitus, including 1025 (6%) with PAD, were ra

173 olute benefits appeared larger in those with diabetes mellitus, including a 3-fold greater reduction

174 ered a culprit in the development of obesity/diabetes mellitus-induced cardiomyopathy.

175 population has given rise to an epidemic of diabetes mellitus-induced heart failure.

176 Diabetes mellitus is a known susceptibility factor for s

177 Diabetes mellitus is a lifelong metabolic disease that r

178 Type 2 diabetes mellitus is a major concern globally and well k

179 Diabetes mellitus is a major contributor to disproportio

180 prevalence of obesity and associated type II diabetes mellitus is a major health concern, particularl

181 Diabetes mellitus is a major risk factor for coronary he

182 In Australia and Europe, diabetes mellitus is almost four times more common among

183 rsonalized, or precision, medicine in type 2 diabetes mellitus is becoming a reality with new insight

184 Type 1 diabetes mellitus is believed to result from destruction

185 n primary prevention populations with type 2 diabetes mellitus is highly heterogeneous.

186 Treatment efficacy for diabetes mellitus is largely determined by assessment of

187 Because diabetes mellitus is the first diagnosed symptom of Wolf

188 Although not fully understood, diabetes mellitus is thought to be associated with cardi

189 blood glucose levels or a family history of diabetes mellitus; 'K', the presence of high urinary or

190 edictive of noncalcified plaque progression, diabetes mellitus mainly led to an increase in calcified

191 ion, and fibronectin retention were found in diabetes mellitus models.

192 ), pharmacologic agents used to treat type 2 diabetes mellitus must show cardiovascular safety.

193 Most studies addressed type 2 diabetes mellitus (n = 85; 36%), hypertension (n = 32; 1

194 ding cancer, cardiovascular diseases, type 2 diabetes mellitus, obesity, amnesia among other disorder

195 atio, 1.01 [95% CI, 1.00-1.02], P=0.031) and diabetes mellitus (odds ratio, 1.87 [95% CI, 1.16-3.02],

196 mited evidence on knowledge of patients with diabetes mellitus on diabetic retinopathy and their eye

197 ined by well-recognized risk factors such as diabetes mellitus or hypertension, emerging risk factors

198 ft ventricular ejection fraction <40% and/or diabetes mellitus (OR, 0.93 [95% CI, 0.74-1.19]), statin

199 Renal and Metabolic Effects in Patients With Diabetes Mellitus, or Prediabetes, and Heart Failure]) t

200 existent morbidities of high blood pressure, diabetes mellitus, osteoporosis, non-AIDS cancer, chroni

201 ovascular and macrovascular complications of diabetes mellitus over 5-10 years.

202 .2 years; p < 0.001) and more likely to have diabetes mellitus (p = 0.004), hypertension, hyperlipide

203 0.94) and dementia (P = 0.77), prevalence of diabetes mellitus (P = 0.16), arterial hypertension (P =

204 Vascular Outcomes Recorded in Patients with Diabetes Mellitus), PEGASUS-TIMI 54 (Prevention of Cardi

205 Permanent neonatal diabetes mellitus (PNDM) is caused by reduced beta-cell

206 ecome a more frequent feature of the broader diabetes mellitus population in both developing and deve

207 equations overestimate risk in veterans with diabetes mellitus, potentially impacting guideline-indic

208 Diabetes mellitus predisposes affected individuals to a

209 prespecified predictors-age >=65 years old, diabetes mellitus, preoperative eGFR, and nephrectomy ty

210 Diabetes mellitus prevalence increased more in men than

211 current smoking, antihypertensive treatment, diabetes mellitus, prevalent heart failure, and prevalen

212 re, hypertension, 65 years of age and older, diabetes mellitus, previous stroke or transient ischemic

213 males, African Americans, and patients with diabetes mellitus provides rationale for monitoring thes

214 Posttransplant diabetes mellitus (PTDM) affects up to 50% of solid orga

215 , 8967 adults <=64 years old reported having diabetes mellitus, representing 13.1 million individuals

216 ut-of-pocket expenditure among patients with diabetes mellitus represents a risk of financial hardshi

217 hypertension (RR, 1.46; 95% CI: 1.06, 2.02), diabetes mellitus (RR, 1.67; 95% CI: 1.20, 2.33), and a

218 These markers may be effective tools for diabetes mellitus screening, diagnosis, and prognosis.

219 us skeletal abnormalities, insulin-dependent diabetes mellitus, sensorineural hearing loss, and mild

220 In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2 inhibi

221 People with prediabetes and diabetes mellitus spend >50% of their time outside the o

222 Type 1 and type 2 diabetes mellitus (T1DM and T2DM) increase the risk of a

223 genetic variation in a mouse model of type 1 diabetes mellitus (T1DM) affects long-distance genomic i

224 two main forms of diabetes mellitus - type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T

225 HbA(1c) in the care of patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T

226 Type 1 diabetes mellitus (T1DM) has traditionally been characte

227 ogenic differences exist in the two forms of diabetes mellitus; T1DM is immune mediated and T2DM is m

228 t increase in the worldwide burden of type 2 diabetes mellitus (T2D) and the accompanying rise of its

229 ailure is a prominent complication of type 2 diabetes mellitus (T2D).

230 ed traditionally in the management of type 2 diabetes mellitus (T2DM) and contain potent bioactive is

231 both the incidence and prevalence of type 2 diabetes mellitus (T2DM) and heart failure (HF) worldwid

232 Currently, type 2 diabetes mellitus (T2DM) and obesity are major global pu

233 ance in metabolic disease, including Type II Diabetes Mellitus (T2DM) and obesity.

234 a well-described feature of obesity, type 2 diabetes mellitus (T2DM) and other insulin-resistant sta

235 every patient, why some patients with type 2 diabetes mellitus (T2DM) develop CVD while others are pr

236 Obesity-associated type 2 diabetes mellitus (T2DM) entails insulin resistance and

237 As the burden of type 2 diabetes mellitus (T2DM) grows in the 21st century, the

238 Patients with Type 2 diabetes mellitus (T2DM) have an increased risk of atria

239 Men with type 2 diabetes mellitus (T2DM) have significantly lower serum

240 ourse of NAFLD (liver fat [LFAT]) and type 2 diabetes mellitus (T2DM) in HIV+ patients with and witho

241 Accumulating data suggest that type 2 diabetes mellitus (T2DM) in younger people (aged <40 yea

242 Type 2 Diabetes mellitus (T2DM) is a disorder characterized by

243 a central nervous system disease and type 2 diabetes MELLITUS (T2DM) is a metabolic disorder, an inc

244 The prevention of type 2 diabetes mellitus (T2DM) is a target priority for the WH

245 Type 2 diabetes mellitus (T2DM) is an established risk factor f

246 Type 2 diabetes mellitus (T2DM) is associated with a higher ris

247 Type 2 diabetes mellitus (T2DM) is characterized by beta-cell d

248 Type 2 diabetes mellitus (T2DM) is characterized by impaired gl

249 h type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) is unassailable, yet HbA(1c) ta

250 -1 receptor agonists for treatment of type 2 diabetes mellitus (T2DM) motivated our search for orally

251 Patients with Type 2 diabetes mellitus (T2DM) show cognitive and mood impairm

252 ve shown that high-risk patients with type 2 diabetes mellitus (T2DM) treated with sodium glucose cot

253 nvestigate the causal associations of type 2 diabetes mellitus (T2DM) with risk of overall cancer and

254 the CVD safety of SGLT2 inhibitors in type 2 diabetes mellitus (T2DM), consistent reductions in risks

255 Type 2 diabetes mellitus (T2DM), dyslipidemia and periodontitis

256 8 pure spectra, presumably related to type 2 diabetes mellitus (T2DM), from their synthetic linear mi

257 t of obesity-related diseases such as type 2 diabetes mellitus (T2DM), hypertension, and dyslipidaemi

258 artery disease (CAD) and concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been co

259 eatment for patients with obesity and type 2 diabetes mellitus (T2DM), there exists reluctance to inc

260 - type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM).

261 d antidiabetic agent in patients with type 2 diabetes mellitus (T2DM).

262 prove the management of patients with type 2 diabetes mellitus (T2DM).

263 rease the risk for the development of type 2 diabetes mellitus (T2DM).

264 e eligibility criteria for those with type 2 diabetes mellitus (T2DM).

265 iabetic individuals and patients with type-2 diabetes mellitus (T2DM, n = 10 each).

266 GT subjects without family history of type 2 diabetes mellitus (T2DM; FH-) and 8 NGT with family hist

267 glucose tolerance [IGT], and 207 with type 2 diabetes mellitus [T2DM]), divided in nonobese and obese

268 ll HDL was lower in the subjects with type 2 diabetes mellitus than the control subjects.

269 In contrast to type 1 diabetes mellitus, the dominant immune cell type causing

270 Despite advances in the treatment of diabetes mellitus, the path toward endogenous renewal of

271 were similar among patients with and without diabetes mellitus, the prespecified net benefit for riva

272 s-sectional study of individuals with type 1 diabetes mellitus, those who were designated to be slow

273 00 mg/dL and a history of atherosclerosis or diabetes mellitus to icosapent ethyl 4 g/d or placebo.

274 ), 33% arterial hypertension (n=75), and 12% diabetes mellitus type II (n=28).

275 ocardial signal pattern (OR, 3.9, P=0.0068), diabetes mellitus type II (OR, 4.1, P=0.046), and beta-b

276 risk factors (overweight [OR, 2.6, P=0.023], diabetes mellitus type II [OR, 2.9, P=0.041], certain ch

277 se with a history of tobacco use, asthma, or diabetes mellitus type II.

278 dels tested associations of geography and/or diabetes mellitus type on the likelihood of SPK versus k

279 onic periodontitis (CP) patients with type-2 diabetes mellitus (type-2 DM) than controls (systemicall

280 y mechanism leading to the two main forms of diabetes mellitus - type 1 diabetes mellitus (T1DM) and

281 emature coronary heart disease, early type 2 diabetes mellitus, ubiquitous abdominal obesity, exposur

282 versus placebo plus aspirin in patients with diabetes mellitus versus without diabetes mellitus in pr

283 Obesity often leads to type 2 diabetes mellitus, via the increased production of proin

284 years (range, 25-75 years), mean duration of diabetes mellitus was 16.1 years (range, 2-36 years), an

285 Diabetes mellitus was found to be more prevalent among S

286 association between H. pylori infection and diabetes mellitus was found.

287 Mean age was 66.3+/-10.9, diabetes mellitus was seen in 19.3% of patients, and 53%

288 e sex, African American race, and history of diabetes mellitus were associated with higher expression

289 Ninety-six patients with diabetes mellitus were included in this prospective stud

290 tion fraction, 26%, and 12 (17%) with type 2 diabetes mellitus were randomized.

291 ars of age (or >=60 years of age if they had diabetes mellitus) were randomized to receive RA or SV g

292 subunit (Kir6.2 and SUR1) result in neonatal diabetes mellitus, whereas loss-of-function mutations ca

293 Diabetes mellitus, which affects more than 463 million p

294 glucose and lipid metabolism associated with diabetes mellitus, which leads to increased oxidative st

295 2 mg versus placebo in patients with type 2 diabetes mellitus, while aiming for glycemic equipoise.

296 le-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for wor

297 d (T2DMpoorly-DL-P) poorly-controlled type 2 diabetes mellitus with dyslipidemia and periodontitis.

298 itis; (T2DMwell-DL-P) well-controlled type 2 diabetes mellitus with dyslipidemia and periodontitis; a

299 ketoacidosis (DKA), a severe complication of diabetes mellitus with potentially fatal consequences, i

300 as a decision aid in individuals with type 2 diabetes mellitus without clinical atherosclerotic cardi